Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
Purpose: The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy accordin...
Saved in:
Main Authors: | Masahiro Fukuoka, Yi Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan Swan Leong, Virote Sriuranpong, Tsu Yi Chao, Kazuhiko Nakagawa, Da Tong Chu, Nagahiro Saijo |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79960702788&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/49702 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018) -
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018) -
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Fukuoka M., et al.
Published: (2017) -
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018) -
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)